niacin extended-release formulation / Generic mfg.  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

   Remove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
niacin extended-release formulation / Generic mfg.
2007-002023-32: Niaspan for the treatment of endothelial dysfunction in patients without hyperlipoproteinemia

Ongoing
2
30
Europe
Niaspan 500 mg, Niaspan 1000 mg, Niaspan 500 mg, Niaspan 1000 mg
Charité - Universitätsmedizin Berlin
Patients in this study do have symptomes like dyspnea, reduced maximum stress and do have a weakness feeling.We are analysing the endothelial function via the FMD-methode: Before and after a Niaspan-treatment of 6 months.
 
 
2007-006393-29: A 4-week double-blind placebo-controlled pilot study, evaluating niacin-induced flushing and lipid parameter effects of V0002 CA 1g 3 capsules/day associated with Niaspan® (from 375 mg to 1000 mg) in addition to usual care statin, in patients suffering from dyslipidemia with uncontrolled elevated triglycerides.

Ongoing
2
120
Europe
V0002 CA, V0002 CA, Niaspan® 375mg Prolonged Release, Niaspan® 500mg Prolonged Release, Niaspan® 750mg Prolonged Release, Niaspan® 1000mg Prolonged Release, Niaspan® 375mg Prolonged Release, Niaspan® 500mg Prolonged Release, Niaspan® 750mg Prolonged Release, Niaspan® 1000mg Prolonged Release
PIERRE FABRE MEDICAMENT represented by Institut de Recherche Pierre Fabre
Dyslipidemia with uncontrolled elevated triglycerides
 
 
MAFLD, NCT06140953: Benefits of Trimetazidine in Pateints

Recruiting
2
60
RoW
conventional treatment, conventional treatment ( anti diabetic drugs and antihyperlipidimic drugs ), Furosemide or other alternatives , Niaspan or other alternatives, conventional therapy, Trimetazidine, furosemide or other alternative , niaspan or other alternative
October 6 University
Non-Alcoholic Fatty Liver Disease
06/24
09/25
NCT05846373: Effect of Nicotinic Acid as Add on Therapy in Patients Receiving β Blocker for Prophylaxis of Moderate to Severe Migraine

Recruiting
2
66
RoW
Nicotinic Acid 500 MG Extended Release Oral Tablet, Niacin, Nicotinic Acid 1000 MG Extended Release Oral Tablet, Placebo
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Migraine Prophylaxis
01/24
01/24

Download Options